Business Segment, Geographic, and Concentration Risk Information (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Summary of Revenue by Segments

Segment information is as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Total revenue:
Oncology Innovation Platform	$	5,730		$	307		$	6,504		$	20,970
Global Supply Chain Platform		6,263			4,887			13,056			11,221
Commercial Platform		19,943			15,791			42,653			29,050
Total revenue for reportable segments		31,936			20,985			62,213			61,241
Intersegment revenue		(420	)		(287	)		(1,555	)		(1,391	)
Total consolidated revenue	$	31,516		$	20,698		$	60,658		$	59,850

Summary of Revenue by Product Group

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Total revenue by product group:
License fees	$	5,723	$	296	$	6,490	$	20,953
Commercial product sales		25,347		19,970		53,271		38,033
Contract manufacturing revenue		439		427		883		857
Other revenue		7		5		14		7
Total consolidated revenue	$	31,516	$	20,698	$	60,658	$	59,850

Summary of Segment Information

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Net loss attributable to Athenex, Inc.:
Oncology Innovation Platform	$	(18,062	)	$	(20,122	)	$	(47,947	)	$	(25,563	)
Global Supply Chain Platform		(3,324	)		(576	)		(4,096	)		(542	)
Commercial Platform		(2,430	)		(10,208	)		(497	)		(26,135	)
Segment total		(23,816	)		(30,906	)		(52,540	)		(52,240	)
Discontinued operations		(8,341	)		(3,368	)		2,963			(7,084	)
Total consolidated net loss attributable to    Athenex, Inc.	$	(32,157	)	$	(34,274	)	$	(49,577	)	$	(59,324	)

Summary of Depreciation, Amortization and Assets by Segment

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Total depreciation and amortization:
Oncology Innovation Platform	$	125	$	224	$	337	$	438
Global Supply Chain Platform		243		266		499		542
Commercial Platform		301		461		634		1,006
Segment total		669		951		1,470		1,986
Discontinued operations		42		242		215		481
Total consolidated depreciation and    amortization	$	711	$	1,193	$	1,685	$	2,467

	June 30,		December 31,
	2022		2021
Total assets:
Oncology Innovation Platform	$	112,759	$	131,432
Global Supply Chain Platform		19,143		19,693
Commercial Platform		63,443		53,113
Segment total		195,345		204,238
Discontinued operations		26,542		63,210
Total consolidated assets	$	221,887	$	267,448

Summary of Revenue by Geographical Segment

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Total revenue:
United States	$	31,509	$	20,679	$	60,644	$	59,323
Other foreign countries		7		19		14		527
Total consolidated revenue	$	31,516	$	20,698	$	60,658	$	59,850

Summary of Property and Equipment by Geographical Segment

	June 30,		December 31,
	2022		2021
Total property and equipment, net:
United States	$	3,757	$	4,196
China		437		985
Total consolidated property and equipment, net	$	4,194	$	5,181

Summary of Customer Revenue and Accounts Receivable Concentration

Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment.

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Percentage of total revenue by customer:
Customer A		18	%		0	%		10	%		33	%
Customer B		16	%		15	%		14	%		14	%
Customer C		15	%		16	%		15	%		16	%
Customer D		13	%		13	%		13	%		13	%

	June 30,			December 31,
	2022			2021
Percentage of total accounts receivable by customer:
Customer A		27	%		35	%
Customer B		23	%		29	%
Customer C		17	%		2	%
Customer D		12	%		15	%